Segmented poly(A) tails with microRNA target sites confer tissue-specific regulation for mRNA therapeutics
Summary
Targeted delivery and controlled expression of mRNA encapsulated by lipid nanoparticles (mRNA-LNPs) are critical for the development of safe and effective mRNA medicines. However, efficient post-delivery regulation of mRNA-LNP expression remains challenging, and conventional approaches largely rely on modifying the 3' UTR at the expense of other regulatory elements. In this study, we engineered segmented poly(A) tail variants that function as gene-specific regulatory elements for synthetic mRNAs, providing an alternative regulatory module that preserves UTR integrity.
Keywords
Targeted delivery and controlled expression of mRNA encapsulated by lipid nanoparticles (mRNA-LNPs) are critical for the development of safe and effective mRNA medicines. However, efficient post-delivery regulation of mRNA-LNP expression remains challenging, and conventional approaches largely rely on modifying the 3' UTR at the expense of other regulatory elements. In this study, we engineered segmented poly(A) tail variants that function as gene-specific regulatory elements for synthetic mRNAs, providing an alternative regulatory module that preserves UTR integrity. Insertion of miR-122 or miR-142 target sites (MTSs) at various positions within the poly(A) tail suppressed luciferase expression in non-target cells in vitro and in vivo in a position-dependent manner. Furthermore, by incorporating triple-MTS sequences for miR-142, miR-126, and miR-148a in all possible combinations at the 5' end of the poly(A) tail, we identified specific arrangements that simultaneously reduced luciferase activity in three non-target hepatic cell types while preserving robust expression in hepatocytes. MTS insertion order proved critical for optimal silencing, highlighting a design parameter not observed in dual-MTS constructs. These findings establish the poly(A) tail as a programmable platform for cell-type-selective regulation, complementing tissue-tropic LNPs and expanding the toolbox for mRNA therapeutic design.
Abstract from PubMed Central (PMID 42835592, PMC13635506). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Advances in Extracellular Vesicle-Based Innovative Drugs Targeting Alzheimer's Disease
International journal of nanomedicinePolymeric Nanomedicines for siRNA Delivery in Hepatocellular Carcinoma: Emerging Therapeutic Strategies, Combination Approaches, and Translational Perspectives
Bioengineering & translational medicineCombined HER2-targeted mRNA-LNP vaccine and radiotherapy suppress Lewis lung carcinoma growth in mice: Efficacy and mechanistic insights
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
